The answer depends on the liver diagnosis
ESSENCE found improvements in biopsy-defined liver outcomes among people with metabolic dysfunction-associated steatohepatitis, or MASH, and stage F2 or F3 fibrosis. It did not study an undifferentiated group of people whose scan merely mentioned fatty liver. That distinction is central to understanding the evidence.[1]
Current US Wegovy labeling includes noncirrhotic MASH with moderate-to-advanced fibrosis, consistent with stages F2–F3, under accelerated approval. This specific indication should not be generalized to every fatty-liver finding, cirrhosis or every product containing semaglutide.[2]
What changed on biopsy
The planned interim analysis assessed the first 800 participants at 72 weeks. MASH resolution without worsening fibrosis occurred in 62.9% with semaglutide and 34.3% with placebo. Fibrosis improvement without worsening MASH occurred in 36.8% and 22.4%. The ongoing trial enrolled 1,197 participants overall and was manufacturer-funded.[1]
| Reading the evidence | What it tells us |
|---|---|
| MASH resolution | Inflammatory disease findings improved without fibrosis becoming worse. |
| Fibrosis improvement | Scarring stage improved without worsening MASH. |
| Not yet the same outcome | A demonstrated reduction in future liver failure, transplantation or death. |
| Population boundary | Noncirrhotic MASH with F2–F3 fibrosis. |
These are meaningful biological outcomes, but they answer a different question from whether a treatment prevents a future hospitalization or transplant. Accelerated approval uses a surrogate endpoint considered reasonably likely to predict clinical benefit; longer-term confirmation remains important.[3]
A scan report is a starting point
A person may first hear about fatty liver after imaging performed for another reason. The next clinical question is what that finding means in the context of blood tests, medical history and any assessment of fibrosis. The advertising phrase “liver health” cannot establish that a person has the condition studied in ESSENCE.
Bring the actual report to the clinician who is evaluating the liver concern. There is no need to interpret an unfamiliar abbreviation alone or to upload it to a comparison website. A useful question is whether the next step is diagnosis, staging, monitoring or treatment. Those are different tasks and may involve different clinicians.
Keep weight and liver outcomes in separate columns
Weight change can be relevant to the wider care conversation, but a lower weight does not itself reveal a biopsy result. Likewise, one laboratory value cannot be substituted for all the outcomes in a trial. The study’s design is useful precisely because it measured more than a scale change.
Our prediabetes article and FLOW kidney article show why each diagnosis has its own population and outcome measures. Evidence from one organ system should not be treated as a blanket guarantee about another.
Organize care around the diagnosis
If a treatment is being considered for MASH, clarify which clinician owns the liver plan and how the prescriber receives relevant results. The arrangement may involve existing primary care and specialist care rather than a standalone weight-loss service. Keep prescription access, liver monitoring and insurance authorization as separate responsibilities.
The GoodLife Health review explains a laboratory-oriented membership, but a laboratory panel alone does not establish specialist liver management. Our provider guides and question builder help compare those responsibilities without recommending a treatment.
For budgeting, distinguish the clinical program from the exact prescribed product and any investigations. An approved indication does not automatically establish coverage under a particular plan. The essential first decision is whether the diagnosis matches the evidence, followed by a coordinated plan for evaluating benefit over time.
Why the two biopsy endpoints are not interchangeable
Resolution of inflammatory disease without worsening scarring and improvement in scarring without worsening inflammatory disease are deliberately different endpoints. A participant can meet one without necessarily meeting the other. Combining their percentages or describing them as one universal cure rate would misrepresent the study. Keep the wording intact when discussing the result.
The same discipline applies to the word “reversal.” A trial can document an improvement in a measured stage without establishing that every future risk has disappeared. For ongoing care, the relevant question is how the clinician will assess the condition over time and what the available measurements can actually show. A plan based on the diagnosis is more useful than a broad promise to optimize liver health.